Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis

Xiang Li 1 · Huan Zheng 2 · Man-Cheng Yu 1 · Wei Wang 1 · Xin-Hong Wu 1 · Dong-Mei Yang 1 · Juan Xu 1

Received: 17 April 2020 / Accepted: 25 June 2020 / Published online: 3 July 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract
Background PEGylated granulocyte colony-stimulating factor (G-CSF) is a safe alternative to G-CSF to improve chemotherapy-induced neutropenia (CIN). This superiority has resulted in its increased use by physicians; however, the superiority of PEGylated G-CSF for CIN in breast cancer has not been conclusively determined.

Objectives To assess the superiority of PEGylated G-CSF for CIN in breast cancer in terms of effectiveness and safety via a systematic review and meta-analysis.

Methods A literature search in PubMed, Embase, Cochrane Library, and Web of Science was performed for eligible studies published from database inception to December 2019. All studies comparing PEGylated G-CSF and G-CSF for CIN of breast cancer were reviewed. After literature selection, data extraction and quality assessment were performed by two reviewers independently. Meta-analysis was conducted using Revman, version 5.2.

Results Nine randomized controlled trials were finally identified. The publication bias of these studies was acceptable. For the endpoint of effectiveness, analysis of the incidence/duration of grade ≥3 neutropenia, the duration of grade 4 neutropenia, the incidence of febrile neutropenia (FN), and the time to absolute neutrophil count recovery showed no advantage of PEGylated G-CSF over G-CSF for CIN of breast cancer (P > 0.05), with the premise of a sufficient dose of G-CSF according to the guidelines.

No significant differences in grade 4 adverse events were observed between the groups (P = 0.29), and PEGylated G-CSF did not increase the incidence of skeletal and/or muscle pain compared with G-CSF (P = 0.32).

Conclusion PEGylated G-CSF was as effective and safe as G-CSF to reduce CIN in breast cancer but did not show an obvious superiority. However, in clinical practice, PEGylated G-CSF has an obvious advantage in terms of convenience, which could improve patient’s quality of life.

Keywords PEGylated G-CSF · G-CSF · Breast cancer · Chemotherapy

Introduction

Although treatments for breast cancer, which is one of the most common cancers diagnosed in women [1], are continuously progressing, chemotherapy still plays a critical role. As early as 1995, a study showed that chemotherapy dose had a marked influence on the treatment effect [2], and further studies found that a sufficient dosage and course of chemotherapy could significantly improve the relapse-free survival and overall survival of patients with breast cancer [3, 4]. However, the toxicities caused by chemotherapy can obviously affect patients’ tolerance and limit the sustained relative dose intensity (RDI) of chemotherapy, which can reduce the dosage and/or the course of chemotherapy, resulting in reducing effectiveness. Among the toxicities of chemotherapy, myelosuppression is a frequent reason for dose limitation and dose reduction in patients with cancer [5]. Moreover, once severe bone marrow suppression occurs, febrile neutropenia (FN) can be life-threatening, with a high risk of mortality. Therefore, clinical researchers have been exploring effective
therapeutic drugs to alleviate chemotherapy-induced neutropenia (CIN) and improve patients’ tolerance of chemotherapy. Granulocyte colony-stimulating factor (G-CSF) is one of the many cytokines that can simulate the proliferation and differentiation of neutrophil precursors and enhance the function of mature neutrophils. As a result, since 1991, the first G-CSF (filgrastim) was approved for use in patients with cancer being treated with chemotherapy. G-CSF-type therapeutic agents were widely used in the clinic to reduce CIN and were accepted in different clinical guidelines for patients receiving high FN chemotherapy regimens. However, because of its primary clearance through the kidney, human G-CSF shows a short half-life, requiring daily administration intravenously or subcutaneously, which means patients suffer increased rates of injection site infection and display reduced tolerance. To extend the half-life, polyethylene glycol (PEG) was introduced into G-CSF (PEGylated G-CSF), which changed the drugs’ method of clearance, resulting in a decrease in the systemic clearance of PEGylated form and a single dose showed efficacy comparable to that of daily injections of normal G-CSF. Compared with the G-CSF, PEGylated G-CSF has benefits in terms of fewer injections, better compliance, and decreased burden for healthcare professionals and patients in various tumors or non-Hodgkin’s lymphoma (NHL). However, Hendler et al. found that both forms of G-CSF could reduce the rate of FN and improve the safety and cost of chemotherapy but found no difference between them, especially in patients with breast cancer. Many studies have shown direct comparative data between PEGylated G-CSF and G-CSF; however, there was no agreement on whether PEGylated G-CSF was better than G-CSF in terms of safety and effectiveness in patients with breast cancer. Therefore, we conducted a systematic review and meta-analysis to capture the available data on the effectiveness and safety of PEGylated G-CSF and G-CSF to compare their prophylaxis of CIN and FN during chemotherapy for breast cancer.

**Methods**

**Eligibility criteria and study selection**

Eligible studies must only compare PEGylated G-CSF and G-CSF to improve CIN in patients with breast cancer and all the studies must be the randomized controlled trials (RCTs), with or without a blinding method. Only peer-reviewed articles with full text available were included. PEGylated G-CSF includes different long-acting PEG conjugates of a short-acting G-CSF, which could increase the plasma half-life. G-CSF refers to all kinds of G-CSF used in chemotherapy. Studies comparing PEGylated G-CSF and G-CSF for other types of cancers or non-RCTs were excluded. Duplicate studies and those with incomplete data were excluded, and when publications were duplicates, the latest studies were included. Studies were restricted to those in the English language and those enrolling adult patients.

**Information sources and search strategy**

Relevant studies were searched in the PubMed, Embase, Cochrane Library, and Web of Science databases, from the date of inception of the databases to December 2019. Two people independently searched the databases with combined Medical Subject Headings (MeSH) and unlimited words. The search words were as follows: breast cancer, breast tumor/ tumor, breast carcinoma, malignant neoplasm of breast, mammary cancer/tumor/carcinoma; PEGylated granulocyte colony stimulating, PEGylated G-CSF, PEG-rhG-CSF, PEG-G-CSF, pegfilgrastim, long-acting G-CSF; granulocyte colony-stimulating factor, G-CSF, rhG-CSF, filgrastim, Neupogen, r-methHuG-CSF, Lenograstim, Zarxio, and so on; and the study types were searched using “randomized controlled trial,” “RCT,” and “randomized/randomized.” We also screened all of the cited articles and related articles and contacted the authors by email if the articles were not available in full text.

**Data collection process**

All relevant published data were extracted. Papers were excluded if they did not report neutropenia-related outcomes. If the study used many different doses of PEGylated G-CSF, we collected the data related to the recognized effective dose, such as 6 mg or 100 μg/kg; however, if they disclosed data for both 6 mg and 100 μg/kg doses, we preferentially acquired the data for 6 mg. Authors of eligible articles were contacted by email if verification of their data was necessary. Data were collected by two different reviewers independently; any errors were checked by a third reviewer.

**Data items**

All the data from the included articles were checked to prevent the inclusion of duplicates. Study characteristics that were considered important were design, chemotherapy regimen, sample size, the time of blood collection, and drug interventions (dose). The clinical outcome features were extracted: primary outcomes included incidence or/and duration of grade ≥ 3 neutropenia in cycle 1. The secondary outcomes were the incidence of FN, the time to absolute neutrophil count (ANC) recovery, and adverse events (AEs). Skeletal and/or muscle pain AEs were highlighted for analysis.
Quality assessment in individual studies

The quality of the studies was assessed by two reviewers independently. For the RCTs, the Cochrane Collaboration tool was used to assess the risk of bias [18]. Any discrepancies in interpretation were resolved by consensus. The Cochrane Collaboration tool assesses six quality items: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias. Based on the reviewers’ judgments, every accepted article was evaluated as having a “low,” “high,” or “unclear” risk of bias.

Data analysis

Statistical analysis was performed using the Cochrane Collaboration’s RevMan software, version 5.2 (Cochrane Collaboration, Oxford, UK). For dichotomous data, the comparative differences between the two groups are shown as risk ratios (RRs). For continuous data, the outcomes of the two groups were expressed as weighted mean differences (WMDs) with 95% confidence intervals (CIs). Tests for heterogeneity were performed using Cochran’s Q statistic and the $I^2$ test, with $P < 0.05$ indicating significant heterogeneity. If the test for heterogeneity was statistically significant, then a random effects model was used; otherwise, the meta-analysis was performed using a fixed effects model.

Results

Study selection and study characteristics

A flowchart detailing the process of study identification and selection following the PRISMA statement is shown in Fig. 1. There were 404 records after duplicates were removed, and after screening the titles and abstracts for relevance, 26 articles were assessed further for eligibility. Among the 26 articles, 17 articles were excluded: 7 articles were only an abstract, 1 article was not in English, 4 articles were only related to long-acting G-CSF, 3 articles included patients with other types of cancer, and 2 articles were not RCTs. Thus, nine studies [19–27] were ultimately included in our present systematic review. Two of the identified papers were by the same author [19, 20]; therefore, we examined the data carefully. We found that the two papers included different samples and were from different publication years; therefore, the data of both papers could be used in the analysis and both papers were accepted. The characteristics of these nine studies are summarized in Table 1, while the outcomes of the nine studies are summarized in Table 2.

Risk of bias within the studies

The risks of bias of all studies were assessed using the Cochrane Collaboration’s tool. All the studies randomly
| Study | Year | Design | Chemotherapy regimen | The time of blood collected | Group | Simple size | Age (years) | CSF Name and Origin | Drug interventions (dose) | Primary points | Follow-up |
|-------|------|--------|----------------------|---------------------------|-------|-------------|-------------|---------------------|--------------------------|---------------|----------|
| Xu [21] | 2019 | RCT | Epirubicin + docetaxel; epirubicin + cyclophosphamide | On days 1, 3, 5, 7, 9, 10, 11, 13, 15, 17, and 21 during cycle 1 or until an ANC \( \geq 2.0 \times 10^9/L \) was reached | PG-CSF | 111 | 48.21 ± 8.55 | HHPG-19K, Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, China | 100 μg/kg on day 3 | Duration of grade ≥ 3 neutropenia | Four cycles |
| Wang [22] | 2019 | RCT | Epirubicin + docetaxel; epirubicin + cyclophosphamide | Daily from the first day of chemotherapy to next cycle | PG-CSF | 60 | 47.58 ± 8.88 | HHPG-19K, Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, China | 100 μg/kg on day 3 | ≥ Grade III ANC neutropenia, adverse events | Two cycles |
| Ashrafi [23] | 2018 | RCT | Doxorubicin + cyclophosphamide | 1 and 2 weeks after chemotherapy | PG-CSF | 12 | 45.3 ± 10.5 | Pegagen, CinnaGen Company, Iran | 6 mg, once | Blood cell counts, adverse events | Two cycles |
| Huang [24] | 2018 | RCT | Adriamycin/epirubicin + cyclophosphamide | Days 0, 3, 5, 7, 9, 11, 13, 17, the blood was collected after chemotherapy | PG-CSF | 24 | 46.5 | Jin You Li, CSPC Pharmaceutical Group Limited, China | 100 μg/kg on day 3 | Grade IV ANC neutropenia, adverse events | Two cycles |
| Xie [25] | 2018 | RCT | Epirubicin + cyclophosphamide; epirubicin + docetaxel; docetaxel + cyclophosphamide | Days 3, 5, 7–11, 13, 15, 17, and 21 of cycle 1, and on days 5, 7, 9, 11, 13, and 21 of subsequent cycles | PG-CSF | 187 | 47.12 ± 8.81 | Shandong New Time Pharmaceutical China | 100 μg/kg on day 3 | Grade IV ANC neutropenia, adverse events | Four cycles |
| Study    | Year | Design   | Chemotherapy regimen       | The time of blood collected | Group | Simple size | Age (years) | CSF Name and Origin | Drug interventions (dose)                                                                 | Primary points | Follow-up |
|----------|------|----------|-----------------------------|----------------------------|-------|-------------|-------------|---------------------|------------------------------------------------------------------------------------------|----------------|-----------|
| Park     | 2017 | RCT      | Doxorubicin + cyclophosphamide + docetaxel | NA                          | PG-CSF | 38          | 47.11 ± 6.37 | Tripegfilgrastim; Dong-A ST, Seoul, Korea | ANC ≥ 5.0 × 10^9/L or for a maximum of 14 days                                        | Grade IV ANC neutropenia, adverse events | Six cycles |
|          |      |          |                             |                             | G-CSF  | 36          | 45.76 ± 8.12 | Filgrastim; NA        | 6 mg on day 2 approximately 24 h after completion of chemotherapy                        |                |           |
| Zhang    | 2015 | RCT      | Doxorubicin + cyclophosphamide + docetaxel | Days 3, 5, 7–11, 13, 15, 17, 21 of the chemotherapy cycle 1 for ANC determination, and if an ANC ≤ 1.0 × 10^9/L, blood samples were collected daily until ANC reached ≥ 2.0 × 10^9/L | PG-CSF | 43          | 47.03        | Pegfilgrastim; NA | 60 μg/kg on day 3 ≥ Grade III One cycle ANC neutropenia, adverse events |                |           |
|          |      |          |                             |                             | G-CSF  | 43          | 48.18        | Filgrastim; NA        | 100 μg/kg on day 3 120 μg/kg on day 3                                                |                |           |
| Park     | 2013 | RCT      | Doxorubicin + cyclophosphamide + docetaxel | NA                          | PG-CSF | 20          | 42.50 ± 5.62 | DA-3031; Dong-A Pharmaceuticals, Seoul, Korea | 3.6 mg on day 2 approximately 24 h after completion of chemotherapy 6 mg on day 2 approximately 24 h after completion of chemotherapy 100 μg/m²/day beginning approximately 24 h after chemotherapy and continued until ANC was documented to be 5 × 10^9/L after nadir, or for up to 10 days | Grade IV ANC neutropenia One cycle |           |
|          |      |          |                             |                             | G-CSF  | 21          | 46.95 ± 9.19 | Leucostim; Dong-A Pharmaceuticals, Seoul, Korea | 3.6 mg on day 2 approximately 24 h after completion of chemotherapy 6 mg on day 2 approximately 24 h after completion of chemotherapy 100 μg/m²/day beginning approximately 24 h after chemotherapy and continued until ANC was documented to be 5 × 10^9/L after nadir, or for up to 10 days | Grade IV ANC neutropenia One cycle |           |
| Holmes   | 2002 | RCT      | Doxorubicin + docetaxel     | NA                          | PG-CSF | 149         | 50.9 ± 11.7  | Pegfilgrastim; NA | 100 μg/m²/day beginning approximately 24 h after chemotherapy                             | Grade IV ANC neutropenia Four cycles |           |
|          |      |          |                             |                             | G-CSF  | 147         | 51.9 ± 11.1  | Filgrastim; NA        | 100 μg/m²/day beginning approximately 24 h after chemotherapy                             | Grade IV ANC neutropenia Four cycles |           |

RCT, randomized control trial; NA, not applicable; G-CSF, granulocyte colony-stimulating factor; PG-CSF, pegylated granulocyte colony-stimulating factor; ANC, absolute neutrophil count.
Table 2 The summary of studies’ outcomes

| Study   | Groups       | The number (cycles) of grade 4 neutropenia | Incidence of grade ≥ 3 neutropenia (%) | Duration of grade 4 neutropenia (days) | Duration of grade ≥ 3 neutropenia (days) | Number of FN | The time to ANC recovery (days) | AEs (grade ≥ 3 level) | AEs (grade 4 level) | AEs Skeletal and/or muscle pain |
|---------|--------------|--------------------------------------------|----------------------------------------|----------------------------------------|------------------------------------------|-------------|-------------------------------|------------------------|------------------------|-------------------------------|
| Xu [21] | PG-CSF-100 μg 37 | 50.54 | 0.61 ± 0.96 | 1.17 ± 1.28 | 5 | NA | 2 | 7 | 7 | 105 |
|         | PG-CSF-6 mg 33 | 50.91 | 0.54 ± 0.88 | 1.32 ± 1.82 | 0 | NA | 3 | 1 | 6 | 107 |
|         | G-CSF 51 | 66.36 | 1.02 ± 1.24 | 2.2 ± 2.17 | 2 | NA | 2 | 3 | 1 | 108 |
| Wang [22] | PG-CSF-100 μg 4 | 30 | 0.10 ± 0.40 | 0.77 ± 1.35 | 0 | NA | 5 | 0 | 4 | 42 |
|         | PG-CSF-150 μg 9 | 26.23 | 0.25 ± 0.65 | 0.67 ± 1.31 | 1 | NA | 2 | 0 | 0 | 24 |
|         | G-CSF 20 | 63.33 | 0.97 ± 1.80 | 3.30 ± 3.37 | 1 | NA | 8 | 2 | 4 | 37 |
| Ashrafi [23] | PG-CSF-6 mg NA | NA | NA | NA | 0 | NA | NA | NA | 5 | 18 |
|         | G-CSF NA | NA | NA | NA | 0 | NA | NA | NA | 0 | 0 |
| Huang [24] | PG-CSF-100 μg 43 | 34.8 | 0.96 ± 1.29 | 6 | NA | 73 | 10 | 6 | 129 |
|         | G-CSF 41 | 22.2 | NA | NA | 0 | NA | NA | NA | 0 | 0 |
| Xie [25] | PG-CSF-100 μg NA | 44.39 | NA | 1.19 ± 1.43 | 8 | NA | 78 | 3 | 6 | 142 |
|         | PG-CSF-6 mg NA | 49.47 | NA | 1.10 ± 1.44 | 6 | NA | 97 | 12 | 22 | 142 |
| Park2017 [19] | PG-CSF-6 mg NA | NA | 2.28 ± 1.14 | NA | 6 | 9.83 ± 1.56 | 35 | 10 | 2 | 36 |
|         | G-CSF NA | NA | 2.08 ± 0.85 | NA | 3 | 10.03 ± 0.75 | 36 | 6 | 6 | 38 |
| Zhang [26] | PG-CSF-60 μg 76 | 76 | NA | 2.09 ± 1.21 | 3 | 1.49 ± 1.39 | 7 | 0 | 2 | 43 |
|         | PG-CSF-100 μg NA | 83 | NA | 1.53 ± 1.16 | 2 | 1.16 ± 1.91 | 9 | 1 | 2 | 39 |
|         | PG-CSF-120 μg NA | 74 | NA | 1.73 ± 0.88 | 5 | 1.24 ± 0.93 | 17 | 2 | 4 | 39 |
|         | G-CSF NA | 90 | NA | 1.69 ± 1.14 | 5 | 1.26 ± 1.31 | 21 | 0 | 7 | 39 |
| Park2013 [20] | PG-CSF-3.6 mg NA | NA | 2.2 ± 1.47 | NA | NA | 10.1 ± 1.8 | NA | NA | 4 | 19 |
|         | PG-CSF-6 mg NA | NA | 2.05 ± 1.05 | NA | NA | 9.9 ± 1.6 | NA | NA | 8 | 21 |
|         | G-CSF NA | NA | 2.48 ± 1.03 | NA | NA | 9.8 ± 0.8 | NA | NA | 6 | 21 |
| Holmes [27] | PG-CSF-100 μg 114 | NA | 1.7 ± 1.5 | NA | 11 | 9.3 | NA | 29 | 37 | NA |
|         | G-CSF 116 | NA | 1.8 ± 1.4 | NA | 18 | 9.7 | NA | 30 | 38 | NA |

NA, not applicable; G-CSF, granulocyte colony-stimulating factor; PG-CSF, pegylated granulocyte colony-stimulating factor; ANC, absolute neutrophil count; AE, adverse events.
assigned the research objects and the outcomes were not affected by the blinded method. The included RCTs had a moderate risk of bias (Fig. 2). The publication bias was evaluated using a funnel plot [28].

**Results of individual studies and synthesis of the results**

**The incidence of grade ≥ 3 neutropenia**

Only five studies [21, 22, 24–26] provided information on the incidence of grade ≥ 3 neutropenia. When we input all the data from these studies into the RevMan software, we found that the heterogeneity among the five studies was significant ($P = 0.003, I^2 = 75\%$); therefore, sensitivity analysis of the five trials was performed. The analysis showed that the results were not substantially influenced by the heterogeneity. Therefore, we used the random effects model to analyze the final outcome, in which we did not observe a significant difference in the incidence of grade ≥ 3 neutropenia between the two groups (RR = 0.87; 95% CI 0.69 to 1.1; $P = 0.26$) (Fig. 3a).

**The duration of grade ≥ 3 neutropenia**

Four studies [21, 22, 25, 26] provided results for the duration of grade ≥ 3 neutropenia. The heterogeneity among the studies was significant ($P < 0.00001, I^2 = 94\%$); however, none of the studies in our analysis significantly influenced the heterogeneity, so we used the random effects model to analyze these data. The outcome showed that the duration of grade ≥ 3 neutropenia between the two groups was not significantly different (WMD = −1.04, 95% CI −2.30 to −0.23, $P = 0.11$) (Fig. 3b).

**The duration of grade 4 neutropenia**

Five studies [19–22, 27] reported the duration of grade 4 neutropenia. There was significant heterogeneity among the studies ($P = 0.01, I^2 = 69\%$), necessitating the use of the random effects model. The results showed that the use of PEGylated G-CSF did not result in a significantly shorter duration of grade 4 neutropenia compared with that of G-CSF (WMD = −0.32, 95% CI 0.67 to 0.03, $P = 0.007$). When we removed Wang’s study [22] from the analysis, the heterogeneity decreased ($P = 0.12, I^2 = 49\%$); however, the data from the Wang’s data did not influence the final result ($P > 0.05$). Thus, although the included studies showed that the use of PEGylated G-CSF resulted a slight improvement in grade 4 neutropenia compared with that of G-CSF, the difference was not significant (Fig. 3c).

**The incidence of FN**

Only one study lacked data on this AE [20]; therefore, the remaining eight trials were used to compare the incidence of
Fig. 3 Forest plot comparing the results of effectiveness between the two groups. a Incidence of grade ≥3 neutropenia; b duration of grade ≥3 neutropenia; c duration of grade 4 neutropenia; d incidence of febrile neutropenia (FN); e the time to ANC recovery.
FN between the two groups. There was no significant heterogeneity among these studies ($P = 0.44, I^2 = 0\%$); therefore, we used the fixed effects model to analyze the results. There was no significant difference between the two groups ($RR = 0.80; 95\% CI 0.50 to 1.28; P = 0.35$) (Fig. 3D); thus, PEGylated G-CSF had no obvious advantage in improving the FN of CIN in patients with breast cancer.

The time to ANC recovery

Five studies [19, 20, 24, 26, 27] reported information concerning the time to ANC recovery. However, the study by Holmes et al. [27] only described the median time of ANC recovery; therefore, we excluded that article from this part of the meta-analysis. The pooled analysis of the results showed no significant difference between the two groups ($RR = 0.80; 95\% CI 0.50 to 1.28; P = 0.35$) (Fig. 3D); thus, PEGylated G-CSF had no obvious advantage in improving the FN of CIN in patients with breast cancer.

The grade 4 AEs of the two groups

Seven studies [19, 21, 22, 24–27] reported the specific numbers of grade 4 AEs. The study by Huang et al. [24] reported no grade 4 AEs; therefore, that study was not included in the analysis. Using a fixed effects model, the pooled results showed that the grade 4 AEs of the two groups were not significantly different ($RR = 0.82; 95\% CI 0.57 to 1.18; P = 0.29$), without significant heterogeneity ($P = 0.17, I^2 = 36\%$) (Fig. 4a).

Skeletal and/or muscle pain

All nine studies [19–27] provided information about this AE. The pooled analysis showed significant heterogeneity among the studies ($P = 0.02, I^2 = 56\%$); therefore, a random effects model was used for the analysis. The results indicated no significant difference between the two groups ($RR = 0.77; 95\% CI 0.53 to 1.10; P = 0.20$) (Fig. 4b).
95% CI 0.46 to 1.29; \( P = 0.32 \) (Fig. 4B). Meanwhile, we also performed a sensitivity analysis of these studies and found that when we removed Xie’s study [25], the heterogeneity decreased (\( P = 0.10, I^2 = 42\% \)); however, the pooled results still showed that there was no difference between the groups in terms of skeletal and/or muscle pain using a fixed effects model (RR = 0.96; 95% CI 0.72 to 1.27; \( P = 0.76 \)). Thus, the use of PEGylated G-CSF did not increase the incidence of skeletal and/or muscle pain significantly compared with that of G-CSF.

**Publication bias**

All nine studies [19–27] provided information about skeletal and/or muscle pain; therefore, we created a funnel plot based on this result, which showed that only one study was outside of the 95% CI, while the rest of the studies lay inside, showing a low distribution around the verticals and indicating an acceptable level of publication bias for these studies (Fig. 5).

**Discussion**

CIN is one of the most common side effects of chemotherapy, which usually leads to chemotherapy dose reduction and/or treatment delay, which might compromise the effectiveness of chemotherapy [29]. The clinical use of G-CSF has greatly improved the safety of chemotherapy. The prophylactic use of G-CSF in chemotherapy significantly reduced the incidence of FN from 24 to 7–16% [19, 30, 31]. Breast cancer has different molecular subtypes, and chemosensitivity might be associated with dose intensity: The higher the relative dose intensity, the higher the response rate of patients with breast cancer, especially those with luminal subtypes [32, 33]. Dose-dense chemotherapy regimens in breast cancer induce a higher rate of CIN, necessitating the daily injection of G-CSF [12, 34]. The emergence of PEGylated G-CSF has greatly reduced the number of injections required, making it more convenient for the patients, especially those who live far away from the hospital. Both types of G-CSF are effective, and Cornes et al. [17] also performed a systematic review of short- versus long-acting G-CSF, but they showed that the two kinds of G-CSF had no difference of effectiveness included different types of cancer. Therefore, because the safety and efficacy of PEGylated G-CSF compared with that of G-CSF for CIN of breast cancer have not been conclusively determined, we conducted an up-to-date systematic review based on RCTs to provide the current best evidence on this topic.

Lambertini et al. [21, 35] suggested that compared with G-CSF, PEGylated G-CSF showed superior efficacy, and for high FN chemotherapy regimens, such as AT (anthracyclines-taxane), resulted in a shorter duration of CIN. However, the results of the present study revealed no significant difference in the efficacy indicators between the two drugs (\( P > 0.05 \)). We did not find a significant difference for the incidence/duration of grade \( \geq 3 \) neutropenia between the two groups (\( P > 0.05 \)), and although in most of the studies the PEGylated G-CSF slightly improved grade 4 neutropenia, the difference was not significant for the duration of grade 4 neutropenia (\( P = 0.007 \)). All the included studies were RCTs, in which the short-acting G-CSF was used according to recommended guidelines, requiring an average of more than six injections to support ANC recovery to \( > 2.0 \times 10^9/L \) or up to 10 days. Our study also showed that when the short-acting G-CSF was used according to the guidelines, the use of PEGylated G-CSF did not result in a shorter time to ANC recovery (\( P = 0.45 \)). However, in the articles [36–38] that showed evidence for greater efficacy of PEGylated G-CSF, this may have been the result of the underdosing of short-acting G-CSF in the non-RCTs, which was possibly closer to the real-world situations [17]. In the real world, though more regular visits to the hospital to receive a daily injection may be a source of better psychosocial support, which also would increase the pain of hypodermic injection and the burden to patients, resulting in missed appointments and patients not receiving a sufficient dose of G-CSF [17, 39]. And, in clinical practice, some physicians had shown that using PEGylated G-CSF could result in significant time savings and the pain decrease for patients by reducing the number of injections, which could improve the quality of life (QOL) and treatment compliance for patients [40–42].

FN is considered a severe complication, which could be life-threatening and is associated with a high risk of mortality. Some studies [27, 43–45] showed that the incidence of FN might be significantly different in cycles 2 to 4 and that PEGylated G-CSF could perform better than G-CSF in support of patients’ recovery from FN. However, our pooled results from eight studies [19, 21–27] showed that PEGylated G-CSF had no obvious advantage over G-CSF in improving FN of CIN in patients with breast cancer (\( P = 0.35 \)). This was possible because we only included the data of the first cycle and all the patients in the control groups received sufficient doses of short-acting G-CSF. Meanwhile, we only included patients with breast cancer, who perhaps had a relatively better prognosis compared with that of other tumors.

AEs occurred in most of the included patients; however, the majority of them were related to chemotherapy and were not serious. Ashrafi reported higher numbers of AEs induced by PEGylated G-CSF [23]; however, seven studies [19, 21, 22, 24–27] reported the specific numbers of grade 4 AEs and the final result showed no significant difference between the two groups for grade 4 AEs (\( P = 0.29 \)), suggesting that PEGylated G-CSF is just as safe as G-CSF. None of the articles reported unexpected AEs related to either drug, such as spleen rupture. The most common adverse reaction induced
by PEGylated G-CSF is skeletal and/or muscle pain [23, 46]. However, the results of the present study showed that PEGylated G-CSF did not significantly increase the incidence of skeletal and/or muscle pain (P = 0.32), and the articles that did report this AE noted only mild to moderate, rather than unbearable, pain. Xu et al. [21] also found that a fixed dosage of PEGylated G-CSF did not influence the effectiveness or increase the related AEs in over- or underweight patients. Meanwhile, Shi et al. [47] found that PEGylated G-CSF did not increase the AEs related to different chemotherapy. Thus, we concluded that PEGylated G-CSF was as safe as G-CSF to treat CIN in patients with breast cancer but did not show an obvious superiority.

Several limitations were associated with the included randomized studies. First, the main limitation was that the included studies were all RCTs with a relatively small size and lacked real-world data, which might have decreased the reliability and could cause bias. Second, different studies used different outcome measurements with different blood collection times, and some FN events might not have been captured accurately because some studies had not made a distinction between FN and FN-related endpoints. Third, PEGylated G-CSF was delivered at two recommended doses and as different types (original or biosimilar), and the included studies did not use the same dose and type of PEGylated G-CSF, although the studies had confirmed that the two doses and types of PEGylated G-CSF were similarly effective [14, 19, 21, 22, 25, 48], which could have led to bias.

In conclusion, when short-acting G-CSF is used at a sufficient dose according to the recommended guidelines, PEGylated G-CSF did not show an obvious advantage over G-CSF in the chemotherapy of patients with breast cancer. However, PEGylated G-CSF facilitates out-patient chemotherapy, improves the patients’ QOL by decreasing the numbers of injections, and reduces the number of hospital visits, especially in the time of COVID-19 pandemic, which could decrease the incidence of COVID-19 infection. In addition, PEGylated G-CSF did not increase the incidence of AEs. Thus, for the chemotherapy of breast cancer, PEGylated G-CSF has no obvious superiority in terms of effectiveness and safety over G-CSF, whereas, in actual clinical practice, it is more convenient.

Author’s contributions LI X. and Zheng H. performed the information retrieval, screened the potential subjects, and extracted and integrated the data independently at the same time; Yu M.C. and Wang W. checked the data and designed the review; Wu X.H. drafted the initial manuscript; Yang Dong-mei and Xu J. reviewed the final manuscript; all the authors approved the final manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
2. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901–906
3. Gray R, Bradley R, Braybrooke J, Davies C, Pan H, Peto R, Bliss J, Cameron D, Mackey J, Del Mastro L, Swain S, Unitch M, Bergh J, Pritchard K, Norton L (2018) Abstract GS1-01: increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials. Cancer Res 78:GS1–G01
4. Lalami Y, Klasterisky J (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 120:163–179
5. Kim HS, Lee SY, Kim JW, Choi YJ, Park IH, Lee KS, Seo JH, Shin SW, Kim YH, Kim JS, Park KH (2016) Incidence and predictors of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy in Korea. Oncology 91:274–282
6. Marsh JC, Ganser A, Studler M (2007) Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol 44:138–147
7. Welte K, Gabrilove J, Bronchud MH, Platzter E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): the first 10 years. BLOOD 88:1907–1929
8. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32
9. Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. ANN ONCOL 21 Suppl 5, v248-51
10. Fernandes R, Mazzarello S, Stober C, Ibrahim M, Dudani S, Perdrizet K, Majeed H, Vandermeer L, Shorr R, Hutton B, Fergusson D, Gyawali B, Clemons M (2018) Primary febrile neutropenia prophylaxis for patients who receive FEC-D chemotherapy for breast cancer: a systematic review. J Glob Oncol 4:1–8
11. Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J (2011) Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 27:79–86
12. Bond TC, Szabo E, Gabriel S, Klasterisky J, Tomey O, Mueller U, Schwartzberg L, Tang B (2018) Meta-analysis and indirect treatment comparison of lipogfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract 24:412–423
13. Kuan JW, Su AT, Leong CF (2017) Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: a systematic review and meta-analysis. J Clin Apher 32:517–542
14. Botteri E, Kryndykova A, Curigliano G (2018) Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: a meta-analysis of randomised clinical trials in breast cancer patients. Eur J Cancer 89:49–55
complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract 22:702–716
40. Montella L, Adddeo R, Guarrasi R, Cennamo G, Faiola V, Capasso E, Caraglia M, Del PS (2010) Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide. Eur J Cancer Care (Engl) 19:200–204
41. Morishita M, Leonard RC (2008) Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Expert Opin Biol Ther 8:993–1001
42. Beveridge RA, Rifkin RM, Moleski RJ, Milkovich G, Reitan JF, Paivanas TA, Jacobs RJ (2003) Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 23:101S–109S
43. Jiang Z, Xu FR, Fan J, Li BJ, Gao JN, Hu JW, Wang XJ, Zhang YQ, Wang JH, Li F, Liu Q, Liu YH, Wang S, Wang YS, Ouyang QC, Hu B, Sun GP, Zhang Y, Zang AM, Fan PZ, Wu CP, Liu J, Zhang HW, Wang W, Hu XC, Tang LL, Zhang J, Bao YY, Geng CZ, Sun Q, Zhang F, Yin YM, Jiang HC, An YH (2018) A multicenter, randomized, controlled, phase IV clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer. Natl Med J China 98:1231–1235
44. Kosaka Y, Tai Y, Masuda N, Takano T, Saikei T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K (2015) Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 23:1137–1143
45. Vogel CL, Wojtkiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184
46. Nakov R, Gattu S, Wang J, Velino M, Shaffar G, Skerjanec A (2018) Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. Brit J Clin Pharmacol 84:2790–2801
47. Shi YK, Chen Q, Zhu YZ, He XH, Wang HQ, Jiang ZF, Chang JH, Liu YP, Wang AL, Luo DQ, Zhang Y, Ke XY, Li WL, Zhang WJ, Wang XW, Zhang YP, Wang JM, Liu XQ (2013) Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. Anti Cancer Drug 24:641–647
48. Puertolas I, Frutos PA, Alcacera MA, Andres R, Salvador M (2018) Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients. Eur J Clin Pharmacol 74:315–321

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.